BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 33172431)

  • 21. Lung adenocarcinoma with sarcomatoid transformation after tyrosine kinase inhibitor treatment and chemotherapy.
    Hsieh MS; Lin MW; Lee YH
    Lung Cancer; 2019 Nov; 137():76-84. PubMed ID: 31561203
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overexpression of KIF18A promotes cell proliferation, inhibits apoptosis, and independently predicts unfavorable prognosis in lung adenocarcinoma.
    Zhong Y; Jiang L; Lin H; Li X; Long X; Zhou Y; Li B; Li Z
    IUBMB Life; 2019 Jul; 71(7):942-955. PubMed ID: 30817091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of ROR1 in patients with renal cancer--a potential diagnostic marker.
    Rabbani H; Ostadkarampour M; Danesh Manesh AH; Basiri A; Jeddi-Tehrani M; Forouzesh F
    Iran Biomed J; 2010 Jul; 14(3):77-82. PubMed ID: 21079657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status.
    Arrieta O; Ramírez-Tirado LA; Caballé-Perez E; Mejia-Perez A; Zatarain-Barrón ZL; Cardona AF; Lozano-Ruíz F; Segura-González M; Cruz-Rico G; Maldonado F; Rosell R
    Thorac Cancer; 2020 Apr; 11(4):1026-1037. PubMed ID: 32072746
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ROR1 sustains caveolae and survival signalling as a scaffold of cavin-1 and caveolin-1.
    Yamaguchi T; Lu C; Ida L; Yanagisawa K; Usukura J; Cheng J; Hotta N; Shimada Y; Isomura H; Suzuki M; Fujimoto T; Takahashi T
    Nat Commun; 2016 Jan; 7():10060. PubMed ID: 26725982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ROR1 expression correlated with poor clinical outcome in human ovarian cancer.
    Zhang H; Qiu J; Ye C; Yang D; Gao L; Su Y; Tang X; Xu N; Zhang D; Xiong L; Mao Y; Li F; Zhu J
    Sci Rep; 2014 Jul; 4():5811. PubMed ID: 25056203
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical significance of serum EGFR gene mutation and serum tumor markers in predicting tyrosine kinase inhibitor efficacy in lung adenocarcinoma.
    Feng LX; Wang J; Yu Z; Song SA; Zhai WX; Dong SH; Yu HS; Zhang Y
    Clin Transl Oncol; 2019 Aug; 21(8):1005-1013. PubMed ID: 30637712
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies.
    Daneshmanesh AH; Porwit A; Hojjat-Farsangi M; Jeddi-Tehrani M; Tamm KP; Grandér D; Lehmann S; Norin S; Shokri F; Rabbani H; Mellstedt H; Österborg A
    Leuk Lymphoma; 2013 Apr; 54(4):843-50. PubMed ID: 22988987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ROR1 and ROR2 play distinct and opposing roles in endometrial cancer.
    Henry CE; Llamosas E; Daniels B; Coopes A; Tang K; Ford CE
    Gynecol Oncol; 2018 Mar; 148(3):576-584. PubMed ID: 29395309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Main histologic types of non-small-cell lung cancer differ in expression of prognosis-related genes.
    Skrzypski M; Dziadziuszko R; Jassem E; Szymanowska-Narloch A; Gulida G; Rzepko R; Biernat W; Taron M; Jelitto-Górska M; Marjański T; Rzyman W; Rosell R; Jassem J
    Clin Lung Cancer; 2013 Nov; 14(6):666-673.e2. PubMed ID: 23870818
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies.
    Dave H; Anver MR; Butcher DO; Brown P; Khan J; Wayne AS; Baskar S; Rader C
    PLoS One; 2012; 7(12):e52655. PubMed ID: 23285131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung.
    Chan AW; Chau SL; Tong JH; Chow C; Kwan JSH; Chung LY; Lung RW; Tong CY; Tin EK; Law PP; Law WT; Ng CSH; Wan IYP; Mok TSK; To KF
    J Thorac Oncol; 2019 Jul; 14(7):1213-1222. PubMed ID: 30978501
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status.
    Pak MG; Lee CH; Lee WJ; Shin DH; Roh MS
    Diagn Pathol; 2015 Jul; 10():99. PubMed ID: 26170125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment.
    Chung KP; Huang YT; Chang YL; Yu CJ; Yang CH; Chang YC; Shih JY; Yang PC
    Chest; 2012 Feb; 141(2):420-428. PubMed ID: 21799026
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Rassenti LZ; Balatti V; Ghia EM; Palamarchuk A; Tomasello L; Fadda P; Pekarsky Y; Widhopf GF; Kipps TJ; Croce CM
    Proc Natl Acad Sci U S A; 2017 Oct; 114(40):10731-10736. PubMed ID: 28923920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Downregulation of receptor tyrosine kinase-like orphan receptor 1 in preeclampsia placenta inhibits human trophoblast cell proliferation, migration, and invasion by PI3K/AKT/mTOR pathway accommodation.
    Chen J; Yue C; Xu J; Zhan Y; Zhao H; Li Y; Ye Y
    Placenta; 2019 Jul; 82():17-24. PubMed ID: 31174622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic Role of Receptor Tyrosine Kinase-Like Orphan Receptors in Intestinal-Type Gastric Cancer.
    Nema R; Patel P; Kumar A
    Asian Pac J Cancer Prev; 2021 Jul; 22(7):2125-2134. PubMed ID: 34319035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.
    Zhao Y; Wang S; Zhang B; Qiao R; Xu J; Zhang L; Zhang Y; Han B
    Target Oncol; 2019 Apr; 14(2):169-178. PubMed ID: 30888598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MiRNA-195-5p Functions as a Tumor Suppressor and a Predictive of Poor Prognosis in Non-small Cell Lung Cancer by Directly Targeting CIAPIN1.
    Zheng J; Xu T; Chen F; Zhang Y
    Pathol Oncol Res; 2019 Jul; 25(3):1181-1190. PubMed ID: 30637589
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thyroid transcription factor-1 as a prognostic indicator for stage IV lung adenocarcinoma with and without EGFR-sensitizing mutations.
    Park JY; Jang SH; Kim HI; Kim JH; Park S; Hwang YI; Jung KS; Seo J; Lee CY; Ko Y; Park YB
    BMC Cancer; 2019 Jun; 19(1):574. PubMed ID: 31196060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.